1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

To buy or not to buy? Ipsen searches for Inspiration

 
• By Sukaina Virji

Ipsen of France has confirmed that its US partner Inspiration Biopharmaceuticals failed to raise third party financing by 30 September 2012. As a result, Ipsen's call option to acquire Inspiration is still in force. In addition, Ipsen only has to pay $7.5 million in return for a warrant for 15% of Inspiration's equity. If Inspiration had managed to raise the external funds, Ipsen would have paid $20 million for the warrant, as per their recently amended agreement (scripintelligence.com, 21 August 2012).

Ipsen of France has confirmed that its US partner Inspiration Biopharmaceuticals failed to raise third party financing by 30 September 2012. As a result, Ipsen's call option to acquire Inspiration is still in force. In addition, Ipsen only has to pay $7.5 million in return for a warrant for 15% of Inspiration's equity. If Inspiration had managed to raise the external funds, Ipsen would have paid $20 million for the warrant, as per their recently amended agreement (scripintelligence.com, 21 August 2012).

The companies had renegotiated their partnership agreement as Inspiration battles through a clinical hold placed on its lead development candidate....

More from Cardiovascular

Merck & Co.’s Enlicitide Poised To Be First Oral PCSK9 Inhibitor To Market

 
• By Jessica Merrill

The company announced positive data from two Phase III trials testing the cholesterol-lowering medicine.

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 
• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 
• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Regeneron Wins PCSK9 Court Battle Against Amgen

 
• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

More from Therapeutic Category

With ACIP Upheaval, Merck & Co. Among Those Left In A Lurch

 
• By Jessica Merrill and Bridget Silverman

Merck’s newly approved Enflonsia for RSV is one of the products that was expected to be recommended for use by the CDC advisory committee in June.

Stock Watch: On Q1 Vaccine Sales And Measles Outbreaks

 
• By Andy Smith

A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.